Consider DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj):subcutaneous administration in ~3 to 5 minutes1

SAME POWERFUL EFFICACY. FASTER ADMINISTRATION.1,2*

Approved across 6 indications spanning a wide range of multiple myeloma patients1

Same powerful efficacy as DARZALEX® across approved indications

View clinical evidence

~3 to 5 minute
subcutaneous administration1

Learn how it works

Six approved indications in multiple myeloma1

Review treatment regimens

Understanding the safety profile

Explore safety data

*DARZALEX FASPRO® is administered by subcutaneous injection over approximately 3 to 5 minutes. In contrast, DARZALEX® (daratumumab) is administered by intravenous infusion over approximately 7, 4, and 3 hours for first, second, and subsequent infusions, respectively.1,2

Daratumumab includes both daratumumab and hyaluronidase-fihj (DARZALEX FASPRO®) for subcutaneous injection and daratumumab (DARZALEX®) for intravenous infusion. Daratumumab and hyaluronidase-fihj for subcutaneous injection has different dosing and administration instructions compared to daratumumab for intravenous infusion.